InvestmentAug 6, 2026, 08:07 PM
Latigo Biotherapeutics Prices Upsized IPO of 19.2M Shares at $18.00
AI Summary
Latigo Biotherapeutics, a clinical-stage biopharmaceutical company, announced the pricing of its upsized initial public offering. The company is offering 19,200,000 shares of common stock at a public price of $18.00 per share, expecting gross proceeds of $345.6 million. The shares are anticipated to begin trading on The Nasdaq Global Select Market under the ticker symbol "LTGO" on August 7, 2026, with the offering expected to close on August 10, 2026.
Key Highlights
- Upsized initial public offering priced at $18.00 per share.
- Offering consists of 19,200,000 shares of common stock.
- Expected gross proceeds to Latigo are $345.6 million.
- Underwriters have a 30-day option for up to 2,880,000 additional shares.
- Shares to begin trading on Nasdaq under "LTGO" on August 7, 2026.
- Offering is expected to close on August 10, 2026.
Price Impact
More from LTGO